Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
S CainiCancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.ORCID 0000-0002-2262-1102
M BrusascoSection of Dermatology, Department of Medicine and Surgery, University of Parma, Parma, Italy.ORCID 0000-0003-1176-7197
G NieroItalian Association of Melanoma Patients (AIMaMe), Rome, Italy.
V De GiorgiDepartment of Dermatology, University of Florence, Florence, Italy.ORCID 0000-0001-6531-7998
M LombardoDepartment of Dermatology, Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
C MassoneDermatology Unit, Galliera Hospital, Genoa, Italy.
M MedriSkin Cancer Unit, Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy.
G PalmieriImmuno-Oncology & Cancer Biotherapies, University of Sassari - Unit of Cancer Genetics, Institute for Genetic and Biomedical Research - National Research Council (IRGB-CNR), Sassari, Italy.ORCID 0000-0002-4350-2276
P QuaglinoDermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Turin, Italy.ORCID 0000-0003-4185-9586
R SattaDepartment of Surgical, Microsurgical and Medical Sciences, Unit of Dermatology, University of Sassari, Sassari, Italy.ORCID 0000-0002-2814-5629
C FelicianiSection of Dermatology, Department of Medicine and Surgery, University of Parma, Parma, Italy.ORCID 0000-0003-0883-3210
S GandiniDivision of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.
I StanganelliSection of Dermatology, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Italian Melanoma Intergroup (IMI), Italian Association of Melanoma Patients (AIMaMe)
University of Parma · ITUniversity of Sassari · ITEnte Ospedaliero Ospedali Galliera · ITEuropean Institute of Oncology · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITOspedale di Circolo e Fondazione Macchi · ITPiedmont Reference Center for Epidemiology and Cancer Prevention · ITUniversity of Florence · ITUniversity of Trieste · ITUniversity of Turin · IT
Funding
Italian Ministry of Health
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19MelanomaDelivery of Health CareHumansItalyPandemicsSARS-CoV-2
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Healthcare and safety of patients with melanoma during the COVID-19 Pandemic in Italy. · full record | OpenQuestion